- Home
- SCLX vs MASK Comparison
SCLX vs MASK Comparison
Compare SCLX & MASK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- MASK
- Stock Information
- Founded
- SCLX 2011
- MASK 2017
- Country
- SCLX United States
- MASK Hong Kong
- Employees
- SCLX N/A
- MASK N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- MASK
- Sector
- SCLX Health Care
- MASK
- Exchange
- SCLX Nasdaq
- MASK NYSE
- Market Cap
- SCLX 33.9M
- MASK 27.7M
- IPO Year
- SCLX N/A
- MASK 2025
- Fundamental
- Price
- SCLX $6.30
- MASK $2.14
- Analyst Decision
- SCLX Strong Buy
- MASK
- Analyst Count
- SCLX 3
- MASK 0
- Target Price
- SCLX $367.50
- MASK N/A
- AVG Volume (30 Days)
- SCLX 100.7K
- MASK 90.8K
- Earning Date
- SCLX 08-12-2025
- MASK 01-01-0001
- Dividend Yield
- SCLX N/A
- MASK N/A
- EPS Growth
- SCLX N/A
- MASK 12.16
- EPS
- SCLX N/A
- MASK 0.19
- Revenue
- SCLX $50,710,000.00
- MASK $4,718,055.00
- Revenue This Year
- SCLX $107.00
- MASK N/A
- Revenue Next Year
- SCLX $82.52
- MASK N/A
- P/E Ratio
- SCLX N/A
- MASK $11.81
- Revenue Growth
- SCLX 7.79
- MASK 7.89
- 52 Week Low
- SCLX $3.60
- MASK $2.00
- 52 Week High
- SCLX $73.50
- MASK $4.19
- Technical
- Relative Strength Index (RSI)
- SCLX 60.64
- MASK N/A
- Support Level
- SCLX $6.00
- MASK N/A
- Resistance Level
- SCLX $6.76
- MASK N/A
- Average True Range (ATR)
- SCLX 0.42
- MASK 0.00
- MACD
- SCLX 0.11
- MASK 0.00
- Stochastic Oscillator
- SCLX 82.06
- MASK 0.00
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About MASK 3 E NETWORK TECHNOLOGY GROUP LTD
3 E Network Technology Group Ltd is a business-to-business (B2B) information technology (IT) business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.